Phenotypic alterations in Rb pathway have more prognostic influence than p53 pathway proteins in oral carcinoma

Modern Pathology

Volumn 18, Issue 8, 2005, Pages 1056-1066

  Jayasurya, R ^a   Sathyan, K M ^a   Lakshminarayanan, K ^a   Abraham, Thomas ^a   Nalinakumari, K R ^a   Abraham, Elizabeth K ^a   Krishnan Nair, M ^a   Kannan, S ^a  

^a REGIONAL CANCER CENTRE   (India)

Author keywords

Cell cycle; cyclin D1; Oral carcinoma; p16; p53; Prognosis; Rb

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLINE; PROTEIN BCL 2; PROTEIN P16; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

AGED; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MULTIVARIATE ANALYSIS; PROGNOSIS; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 24044453218     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800387     Document Type: Article

References (31)

1. Parkin DM, Muir CS, Whelam SL, et al (eds). Cancer Incidence in Five Continents. Volume VI. International Agency for Research on Cancer: Lyon, 1992.
2. Moore SR, Johnson NW, Pierce AM, et al. The epidemiology of mouth cancer: a review of global incidence. Oral Dis 2000;6:65-74.
3. Silverman Jr S. Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge. J Am Dent Assoc 2001;132(Suppl):7S-11S.
4. Sherr CJ. Cancer cell cycle. Science (Washington DC) 1996;274:1672-1677.
5. Okami K, Reed Al, Cairns P, et al. Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Oncogene 1999;18:3541-3545.
6. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-330.
7. King KL, Cidlowski JA. Cell cycle and apoptosis: common pathways to life and death. J Cell Biochem 1995;58:175-180.
8. Li Y, Jenkins C, Nichols M, et al. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 1994;14:31-35.
9. Jayasurya R, Francis G, Kannan S, et al. p53, p16 and cyclin D1: molecular determinants of radiotherapy treatment response in oral carcinoma. Int J Cancer 2004;109:710-716.
10. Todd R, Hinds PW, Munger K, et al. Cell cycle dysregulation in oral Cancer. Crit Rev Oral Biol Med 2002;13:50-61.
11. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2002;2:910-917.
12. INK4a/CDKN2A tumour suppressor and its relatives. Biochem Biophys Acta Rev Cancer 1998;1378:115-177.
13. Masuda M, Suzui M, Yasumatu R, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002;62:3351-3355.
14. Bova RJ, Quinn DI, Nankervis JS, et al. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 1999;5:2810-2819.
15. Coqueret O. Linking cyclins to transcriptional control. Gene 2002;299:35-55.
16. Lamb J, Ramaswamy S, Ford HL, et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 2003;114: 323-334.
17. Miracca EC, Kowalski LP, Nagai MA. High prevalence of p16 genetic alterations in head and neck tumors. Br J Cancer 1999;81:677-683.
18. Esteller M, Corn PG, Baylin B, et al. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-3229.
19. Pande P, Soni S, Kaur J, et al. Prognostic factors in betel and tobacco related oral cancer. Oral Oncol 2002;38:491-499.
20. Danahey DG, Tobin EJ, Schuller DE, et al. p16 mutation frequency and clinical correlation in head and neck cancer. Acta Otolaryngol 1999;119: 285-288.
21. Roskell DE, Biddolph SC. Proliferating cell nuclear antigen expression grossly over-estimates cellular proliferation in cardiac myxomas. Eur J Med Res 1999;26:105-106.
22. Namazie A, Alavi S, Oiopade OI, et al. Cyclin D1 amplification and p16 (MST1/CDK41) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope 2002;112:472-481.
23. Stephan CW, Lane DP. Mutant confirmation of p53: precise epitope mapping using a filamentous phage epitope library. J Mol Biol 1992;225:577-583.
24. Mineta H, Borg A, Dictor M, et al. p53 mutation, but not overexpression, correlates with survival in head and neck squamous cell carcinoma. Br J Cancer 1998; 78:1084-1090.
25. Shin DM, Lee JS, Lippman SM, et al. p53 expression: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:519-529.
26. Rayband-Diogene H, Fortin A, Morency R, et al. Markers of radioresistance in squamous cell carcinoma of the head and neck: a clinicopathologic and immunohistochemical study. J Clin Oncol 1997;16:1030-1038.
27. Caminero MJ, Nunez F, Suarez C, et al. Detection of p53 protein in oropharyngeal carcinoma. Prognostic implications. Arch Otolaryngol Head Neck Surg 1996; 122:769-772.
28. Yao L, Iwai M, Furuta I. Correlations of bc12 and p53 expression with clinicopathological features in tongue squamous cell carcinomas. Oral Oncol 1999;35:56-62.
29. Gleich LL, Salamone FN. Molecular genetics of head and neck cancer. Cancer Control 2002;9:369-378.
30. Balz V, Scheckenbach K, Götte K, et al. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 2003;63:1188-1191.
31. ARF tumor suppressor pathway in low grade diffuse astrocytomas and its influence on clinical course. Clin Cancer Res 2003;9: 4884-4890.